Aptorum Group Limited Strengthens Its Presence in the US With the Appointment of Dr. Kira Sheinerman
June 15 2020 - 8:00AM
Business Wire
Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company
focused on the development of novel therapeutics to address global
unmet medical needs, today announced the appointment of Dr. Kira
Sheinerman as the senior strategic consultant based in New York
effective immediately.
“We are really excited to welcome Dr. Sheinerman to the team,”
said Mr. Ian Huen, CEO and Executive Director of Aptorum Group.
“Dr. Sheinerman has comprehensive professional experience in the
life sciences and investment banking sectors, with an outstanding
track record working with emerging growth biotech companies. Her
expertise would inevitably strengthen our strategic initiatives for
the US market and be a valuable addition to our team in enhancing
our global expansion plan.”
Kira Sheinerman is the co-founder, CEO and Executive Director of
DiamiR Biosciences, a molecular diagnostics company focused on
developing blood-based tests for early detection and monitoring of
brain health conditions. Dr. Sheinerman also serves as a Managing
Director, Healthcare Investment Banking at H.C. Wainwright &
Co. Previously, she was a Managing Director at Rodman &
Renshaw, where she worked on financial and strategic transactions
for growth biotech companies with a focus on CNS, oncology, and
infectious diseases, as well as molecular diagnostics. Prior to
healthcare investment banking, Dr. Sheinerman worked at the Arcus
group, a life sciences strategic consulting firm. She is a board
member of the Boyce Thompson Institute, an affiliate of Cornell
University. Dr. Sheinerman received her Ph.D. in Biomedical
Sciences from the Mount Sinai School of Medicine in New York for
her work on molecular mechanisms of Alzheimer's disease. She also
holds an MBA from the Honors program at the Zicklin School of
Business, Baruch College, City University of New York.
About Aptorum Group
Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company
dedicated to developing and commercializing novel therapeutics to
tackle unmet medical needs. Aptorum Group’s current drug pipeline
includes indications in orphan diseases, infectious diseases and
metabolic diseases, a number of which are targeted to enter
clinical trial phases in H2 2020. Aptorum Group is also launching a
women’s health supplement, Dioscorea Opposita Bioactive
Nutraceutical Tablets, which is ready for commercialisation.
For more information about the Company, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as "may," "should," "expects," "plans," "anticipates,"
"could," "intends," "target," "projects," "contemplates,"
"believes," "estimates," "predicts," "potential," or "continue," or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future. As a result, the projections included
in such forward-looking statements are subject to change and could
be materially different from those described herein. Aptorum Group
assumes no obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200615005225/en/
Investor Relations: Tel: +852 3953 7700 Email:
investor.relations@aptorumgroup.com
U.S. Investor Relations RedChip Companies, Inc. Dave Gentry Tel:
(407) 491-4498
Media Tel: + 852 3953 7700 Email: info@aptorumgroup.com
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Sep 2023 to Sep 2024